Pyrimidine Heterocyclic Compound Crystal Form A for KRASG12C Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KRAS-driven cancers, particularly those with mutations like G12C, lack effective therapeutic options due to the challenging druggability of the KRAS protein.
Innovation Solution
A novel compound represented by formula (II) and its crystal form A, characterized by specific X-ray powder diffraction patterns, are developed. This compound demonstrates inhibitory activity against KRASG12C-mutated cells and exhibits stability in various biological matrices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional small molecule inhibitors are used to target KRAS, then irreversible covalent bonds can be formed with cysteine residues, but the druggability remains poor for most KRAS mutations
Solution Approach 1:
The patent modifies the chemical structure parameters of the inhibitor molecule by introducing a pyrimidine heterocyclic compound with specific substituents (R1-R6 groups) and varying n values (0-3). This structural parameter change enables the compound to achieve both covalent binding capability and broader mutation type adaptability, resolving the contradiction between effectiveness and versatility.
2Reliability
If a novel pyrimidine heterocyclic compound is developed to improve anti-tumor activity, then cell proliferation inhibitory activity increases, but the complexity of characterizing and optimizing crystal forms increases
Solution Approach 1:
The patent segments the development process into distinct crystal forms (Form A, Form B, etc.) with clearly defined XRPD patterns. Each crystal form is characterized and optimized independently, allowing systematic evaluation of pharmacokinetic properties without overwhelming complexity. This segmentation enables methodical optimization while maintaining clear tracking of structure-property relationships.
3Reliability
If the compound is optimized for potent inhibitory activity against KRASG12C, then anti-tumor effect improves, but stability in biological matrices may be compromised
Solution Approach 1:
The patent introduces different substituent groups (R1-R6) at specific positions on the pyrimidine core structure, creating local variations in chemical properties. These localized modifications allow the molecule to maintain high affinity for KRASG12C at the binding site while simultaneously improving overall stability in biological matrices through steric protection or electronic effects at different molecular regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound shows potent cell proliferation inhibitory activity on KRASG12C-mutated cell lines, maintains stability in liver microsomes, hepatocytes, plasma, and whole blood, and possesses significant anti-tumor effects, while the crystal form A is stable and retains good pharmacokinetic properties.
Implementation Method 1
Both AMG 510 and MRTX849 are irreversible small molecule inhibitors that inhibit KRAS activity by forming irreversible covalent bonds with cysteine residues of KRAS G12C mutant protein
Implementation Method 2
crystal form A, which is characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ angles of 8.514±0.200°, 14.689±0.200°, and 18.122±0.200°
Data Source
AI summary
A crystal form of a pyrimidine heterocyclic compound and a preparation method therefor. Specifically disclosed are a preparation method for and application of a compound of formula (II) and the crystal form thereof.